Global Pharmaceutical Stability & Storage Services Market is valued at approximately USD 2.7 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 5.5% over the forecast period 2022-2028. Pharmaceutical firms, biotech companies, contract research groups, and other end-users relied heavily on worldwide pharmaceutical stability and storage service providers. These organisations have been working hard to generate pharmaceutical samples, APIs, small and big compounds, and other pharmaceutical goods. Because of the high burden of chronic and infectious diseases, the global industry has seen significant expansion as a result of growing R&D spending by pharmaceutical companies. Pharmaceutical companies are increasingly relying on R&D to remain competitive and versatile. According to Evaluate Pharma, pharmaceutical R&D investment amounted to USD 182 billion in 2018, with a 16.5 percent increase to USD 212 billion in 2021. The government’s growing vaccine campaign is likely to increase demand for commercial COVID-19 vaccine stability and storage. Pharmaceutical R&D spending has increased significantly in recent years. The number of drugs in the clinical stage is expected to increase as R&D spending increases. Each phase of a clinical trial must pass stability testing before it can be approved. This is fueling the market’s expansion. Also, the increasing global burden of these diseases is likely to drive demand for biosimilars and, as a result, demand for biosimilar stability and storage. Different regulatory agencies have different data requirements and testing criteria for assessing stability, which makes marketing products problematic, especially across markets.
The key regions considered for the global Pharmaceutical Stability & Storage Services market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the pharmaceutical stability and storage industry. This is due to a large number of pharmaceutical businesses in the United States and Canada. The presence of prominent market players in this region providing stability and storage services is projected to considerably contribute to market growth. Over the projection period, Asia Pacific is expected to develop at the fastest CAGR because of the existence of countries such as China, India, and Japan, the area has the fastest expanding pharmaceutical market. Initiatives by public entities to cut drug prices in order to improve access to quality medicines have contributed to market growth.
Major market players included in this report are:
Charles River Laboratories International, Inc.
Eurofins Scientific SE
Intertek Group plc
Element Materials Technology
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028
Target Audience of the Global Pharmaceutical Stability & Storage Services Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Value-Added Resellers (VARs)
Third-party knowledge providers